Genentech, Inc.
A single plant registered with the FDA to make drugs for the US market. Below is where it is and the drugs whose FDA labels list this site as performing a manufacturing step — so if this plant has a problem, these are the products that could be affected.
- Country
- United States
- Registered address
- 1 DNA Way, South San Francisco, California (CA) 94080, United States (USA)
- Operations here
- analysisapi manufacturelabelmanufacturepack
- FDA identifiers
- FEI 2917293 · DUNS 080129000
FDA inspection history
Outcomes of closed FDA inspections at this site (drug and biologic program areas).
- NAIDrug Quality Assurance2026-05-15
- NAIBioresearch Monitoring2026-04-07
- NAIBioresearch Monitoring2025-04-21
- VAIBioresearch Monitoring2024-05-02
- NAIDrug Quality Assurance2024-03-20
- VAIBioresearch Monitoring2024-03-12
- VAIBioresearch Monitoring2023-08-11
- NAIBioresearch Monitoring2023-02-21
- NAIBioresearch Monitoring2022-10-07
- NAIBioresearch Monitoring2019-04-02
- NAIBioresearch Monitoring2017-08-03
- NAIBioresearch Monitoring2017-07-12
- NAIBioresearch Monitoring2017-02-01
- NAIBioresearch Monitoring2016-09-16
- VAIDrug Quality Assurance2016-07-08
- NAIBioresearch Monitoring2016-03-16
- NAIBioresearch Monitoring2015-09-30
- NAIBioresearch Monitoring2015-05-15
- NAIDrug Quality Assurance2014-05-02
- NAIDrug Quality Assurance2014-02-21
- VAIBioresearch Monitoring2014-02-21
- NAIBioresearch Monitoring2013-08-02
- NAIDrug Quality Assurance2013-07-17
- VAIBioresearch Monitoring2012-10-23
- NAIDrug Quality Assurance2012-08-29
Drugs this plant is listed as making
18 distinct drugs across 31 products name this site in their FDA label.
- Ado-Trastuzumab EmtansineGenentech, Inc.
- atezolizumabGenentech, Inc.
- atezolizumab and hyaluronidase-tqjsGenentech, Inc.
- bevacizumabGenentech, Inc.
- CrovalimabGenentech, Inc.
- dornase alfaGenentech, Inc.
- GlofitamabGenentech, Inc.
- obinutuzumabGenentech, Inc.
- ocrelizumabGenentech, Inc.
- ocrelizumab and hyaluronidaseGenentech, Inc.
- omalizumabGenentech, Inc.
- pertuzumab, trastuzumab, and hyaluronidase-zzxfGenentech, Inc.
- polatuzumab vedotinGenentech, Inc.
- rituximabGenentech, Inc.
- rituximab and hyaluronidaseGenentech, Inc.
- tenecteplaseGenentech, Inc.
- TrastuzumabGenentech, Inc.
- Trastuzumab and hyaluronidase-oyskGenentech, Inc.
Sources:the establishment's name, address, and country from FDA's Drug Establishments Current Registration Site (DECRS); the drug-to-facility links from DailyMed SPL drug labels, matched by the facility's DUNS number; inspection outcomes from the FDA Data Dashboard, matched by FEI; shortage status from FDA's drug shortage database. More on how this is built. Educational only.